AIM： To investigate the expression of survivin during the early stages of hepatocellular cardnoma （HCC）.METHODS： Immunohistochemical expression of survivin in liver tumor and non-tumor tissue specimens taken from ...AIM： To investigate the expression of survivin during the early stages of hepatocellular cardnoma （HCC）.METHODS： Immunohistochemical expression of survivin in liver tumor and non-tumor tissue specimens taken from 17 patients was compared. In addition, to determine the survivin expression in response to anticancer drugs in early stage HCC, the survivin expression was determined after the treatment of the HCC cells with anti-cancer drugs under hypoxic culture conditions.RESULTS： Survivin proteins were expressed in 64.7% of cells in early HCC specimens. A correlation between the survivin expression rate in the peritumoral hepatocytes and the rate of expression in the HCC specimens （low-rate group vs high-rate group） was observed. The survivin protein concentration in HCC cells was increased by the combination of hypoxia and anti-cancer drugs.CONCLUSION： This study suggests that survivin could be used as a therapeutic target in early HCC.展开更多
Accumulating evidence has shown that the hypoxic microenvironment, which is critical during cancer development, plays a key role in regulating breast cancer progression and metastasis. The effects of hypoxia-inducible...Accumulating evidence has shown that the hypoxic microenvironment, which is critical during cancer development, plays a key role in regulating breast cancer progression and metastasis. The effects of hypoxia-inducible factor 1 （HIF-1）, a master regulator of the hypoxic response, have been extensively studied during these processes. In this review, we focus on the roles of HIF-1 in regulating breast cancer cell metastasis, specifically its effects on multiple key steps of metastasis, such as epithelial-mesenchymal transition （EMT）, invasion, extravasation, and metastatic niche formation. We also discuss the roles of HIF-l-regulated non-coding RNAs in breast cancer metastasis, and therapeutic opportunities for breast cancer through targeting the HIF-1 pathway,展开更多
文摘AIM： To investigate the expression of survivin during the early stages of hepatocellular cardnoma （HCC）.METHODS： Immunohistochemical expression of survivin in liver tumor and non-tumor tissue specimens taken from 17 patients was compared. In addition, to determine the survivin expression in response to anticancer drugs in early stage HCC, the survivin expression was determined after the treatment of the HCC cells with anti-cancer drugs under hypoxic culture conditions.RESULTS： Survivin proteins were expressed in 64.7% of cells in early HCC specimens. A correlation between the survivin expression rate in the peritumoral hepatocytes and the rate of expression in the HCC specimens （low-rate group vs high-rate group） was observed. The survivin protein concentration in HCC cells was increased by the combination of hypoxia and anti-cancer drugs.CONCLUSION： This study suggests that survivin could be used as a therapeutic target in early HCC.
基金supported partially by the National Basic Research Program(973)of China(Nos.2014CB910604 and 2012CB910104)the National Natural Science Foundation of China(Nos.31171358 and 31371429)+2 种基金the Research Fund for the Doctoral Program of Higher Education of China(No.20133402110020)the Fundamental Research Funds for the Central Universities in Chinathe ‘1000 Youth Talent Program’ by the Chinese Government for Hua-feng ZHANG
文摘Accumulating evidence has shown that the hypoxic microenvironment, which is critical during cancer development, plays a key role in regulating breast cancer progression and metastasis. The effects of hypoxia-inducible factor 1 （HIF-1）, a master regulator of the hypoxic response, have been extensively studied during these processes. In this review, we focus on the roles of HIF-1 in regulating breast cancer cell metastasis, specifically its effects on multiple key steps of metastasis, such as epithelial-mesenchymal transition （EMT）, invasion, extravasation, and metastatic niche formation. We also discuss the roles of HIF-l-regulated non-coding RNAs in breast cancer metastasis, and therapeutic opportunities for breast cancer through targeting the HIF-1 pathway,
